HSPA1A and plasma cell myeloma: Dickkopf-1 (DKK1), an ideal target for the immunotherapy of multiple myeloma, was conjugated to HSP70 as a DNA vaccine, and this constructed cancer vaccine was proved to have prophylactic and therapeutic anti-tumor effects through eliciting strong humoral and cellular immune responses in multiple myeloma [202].